Authored by: Heyli Arcese, BA

Psychedelic-assisted therapy is rapidly gaining attention as a promising treatment for conditions like depression, anxiety, and post-traumatic stress disorder. Clinical trials of psilocybin, for example, have shown encouraging results, with some patients experiencing remission from their symptoms after just one session (Carhart-Harris et al., 2018; von Rotz et al., 2022). While much of the public's attention is focused on the psychedelic experience itself, a crucial yet often overlooked part of the change is what happens after the trip—the integration process. Integration refers to how individuals process, understand, and apply insights from their psychedelic experience to foster lasting change (Bathje, Majeski & Kudowor, 2022). Even the most transformative experiences can fade without proper integration and leave individuals without a clear direction for incorporating insights into everyday life. In essence, the psychedelic experience sparks change while integration sustains it. This article explores why integration matters and offers practical strategies to promote meaningful, long-term improvements in mental health after a psychedelic experience.

The Science of Integration: Why It Matters

Psychedelics are known to affect mood (Griffiths et al., 2006, 2008, 2011) and brain function (Carhart-Harris et al., 2017), with effects that can linger long after the drug's effects have worn off. One of the most promising effects is increased neuroplasticity—the brain's ability to reorganize itself in response to new experiences (Gulyaeva, 2017). This phenomenon is auspicious because disruptions in neuroplasticity are linked to mood disorders and addiction (Ray, Shannon Weickert &Webster, 2014). However, these positive changes in brain function may not lead to long-term improvements without active reinforcement post-trip. Many theories posit that benefits gained from psychedelic experiences need ongoing support and processing to result in lasting change (Bathje, Majeski & Kudowor, 2022). Without this effort, the mind may return to its previous patterns, and the new insights gained from the experience may not stick.

Additionally, psychedelic experiences can sometimes bring up intense emotions or even traumatic memories (Watts et al., 2017). Without proper integration, these experiences might feel confusing or overwhelming in the days and weeks following a trip. Integration can help individuals make sense of these emotions and memories, allowing them to process them healthily. Many people who have undergone psychedelic-assisted therapy cite integration as a key piece of their transformative experiences (Watts et al., 2017).

Four Practical Strategies for Integration

1. Guided Reflection and Psychotherapy – Engaging in psychotherapy, particularly approaches like cognitive-behavioural therapy (CBT) or acceptance and commitment therapy (ACT), can help individuals process their experiences and apply insights in a structured way (Sloshower et al., 2020; Gorman et al., 2021). Therapists trained in psychedelic integration can help individuals make sense of symbolic or emotionally intense experiences.
2. Journaling and Creative Expression – Writing about the experience or expressing oneself through art (such as painting or music) can help individuals process emotions that may be difficult to articulate. Creative expression can provide a valuable outlet for understanding and releasing complex feelings, which can improve emotional processing and mental health outcomes (Pennebaker & Chung, 2011).
3. Meditation and Mindfulness Practices – Mindfulness practices can help reinforce new thinking patterns and emotional regulation. Mindfulness practices promote self-awareness and reduce rumination, key elements for achieving long-term therapeutic change (Garland et al., 2015).
4. Community and Support Groups – Peer support groups, such as psychedelic integration circles, offer a safe and supportive space to share experiences with others who have undergone similar journeys. Many participants in psychedelic-assisted psychotherapy trials have emphasized the importance of connecting with others to validate their experiences and reinforce the therapeutic benefits of their trip (Bossis, 2015; Bradberry et al., 2017). These groups help individuals feel understood and supported in their ongoing integration process.

Conclusion

The transformative power of psychedelic-assisted therapy lies not just in the trip itself but in how individuals integrate their experiences into their everyday lives. As psychedelic treatments continue to gain popularity, the field must place greater emphasis on integration strategies that support lasting therapeutic outcomes. If you have had a psychedelic experience or are considering therapy, seeking out trained integration therapists, engaging in mindfulness practices, and connecting with support groups can help ensure that the benefits of the experience continue to unfold long after the trip is over. As research progresses, we will continue to learn more about the best practices for integration and how they can lead to long-term improvements in mental health.

References

• Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology, 13, 824077.
• Bossis, A. P. (2015). Psilocybin-Generated Mystical Experience Research: Implications for Alleviating Existential Distress Associated with a Cancer Diagnosis. Public lecture, UCSF Osher Center for Integrative Medicine, San Francisco, CA, October 26, 2015.
• Bradberry, M., Byler, D., Gilpin, G., Host-Jablonski, D., & Brown, C. (2017). PANEL: UW Psilocybin Pharmacokinetics Study: Study Volunteers Discussion. Psychedelic Science 2017, Oakland, California, April 22, 2017.
• Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 42(11), 2105–2113.
• Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399-408.
• Garland, E. L., Farb, N. A., Goldin, P. R., & Fredrickson, B. L. (2015). Mindfulness broadens awareness and builds eudaimonic meaning: A process model of mindful positive emotion regulation. Psychological Inquiry, 26(4), 293-314.
• Gashi, L., Sandberg, S., & Pedersen, W. (2021). Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy, 87.
• Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021). Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. Frontiers in Psychology, 12, 645246. https://doi.org/10.3389/fpsyg.2021.645246
• Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology (Oxford, England), 22(6), 621–632.
• Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. https://doi.org/10.1007/s00213-011-2358-5
• Gulyaeva, N. V. (2017). Molecular mechanisms of neuroplasticity: an expanding universe. Biochemistry (Moscow), 82, 237–42.
• Ly, C., Greb, A. C., Cameron, L. P., Wong, S., Barragan, E. V., Wilson, P. A., ... & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182.
• Pennebaker, J. W., & Chung, C. K. (2011). Expressive writing: Connections to physical and mental health. In H. S. Friedman (Ed.), The Oxford handbook of health psychology (pp. 417–437). Oxford University Press.
• Price, R. B., & Duman, R. (2020). Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Molecular Psychiatry, 25(3), 530–543.
• Ray, M. T., Shannon Weickert, C., & Webster, M. J. (2014). Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Translational Psychiatry, 4, e389.
• Sloshower, J., Guss, J., Krause, R., Wallace, R. M., Williams, M. T., Reed, S., et al. (2020). Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. Journal of Contextual Behavioral Science, 15, 12–19.
• von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2022). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809.
• Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased ‘connectedness’ and ‘acceptance’ after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520-564.